ESMO 2025 – Roche sticks it to its SERD rivals
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
ESMO 2025 – Lilly strengthens Verzenio’s case
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
ESMO 2025 preview – Astra joins the folate fray
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Lilly moves to overtake Relay
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
